Efficacy and Safety Study of Xyotax to Treat Prostate Cancer

NCT ID: NCT00446836

Last Updated: 2016-03-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 29 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-03-31
• Study Completion Date: 2008-01-31

Brief Summary

The purpose of this study is to determine whether Xyotax, a conjugate of the taxane drug paclitaxel, is effective in the treatment of prostate cancer that is no longer responsive to hormone therapy.

Detailed Description

Prostate cancer is the second leading cause of cancer death in American men. Hormonal ablation, in the form of medical or surgical castration, is the cornerstone of management for metastatic prostate cancer; however, treatment options for a patient in whom androgen ablation fails are limited. Docetaxel and paclitaxel, taxanes that are cell cycle specific, play a major role in advanced hormone-refractory prostate cancer treatment. In preclinical studies, Xyotax, a conjugate of paclitaxel with enhanced permeability and retention in tumor tissue, has an improved therapeutic profile, with both decreased systemic drug-related toxicities and enhanced efficacy. Xyotax as a single agent has been studied in a broad variety of syngeneic and xenogeneic tumor models. Recognizing that taxanes are active in prostate cancer and preclinical data reports activity with Xyotax in docetaxel and paclitaxel resistant cell lines, there is significant rationale to develop this agent in prostate cancer. Thus, a phase II study is needed to evaluate the antitumor activity in two subsets of hormone refractory prostate cancer patients: those with no prior systemic and those with one prior systemic therapy.

Conditions

Prostatic Neoplasms

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Single arm

Open label use of Xyotax

Group Type: OTHER

Paclitaxel polyglumex (Xyotax)

Intervention Type: DRUG

biologically enhanced chemotherapeutic

Interventions

Paclitaxel polyglumex (Xyotax)

biologically enhanced chemotherapeutic

Intervention Type: DRUG

Other Intervention Names

Xyotax

Eligibility Criteria

Inclusion Criteria

• Progressing adenocarcinoma of the prostate having failed prior hormone therapy
• Free of serious co-morbidity
• Have a life expectancy of ≥ 24 weeks
• Maintaining castrate status (either surgically or hormonally)

Exclusion Criteria

• Patients with central nervous system metastases, except those patients who have had excision or radiotherapy and remain asymptomatic, off steroids and with no evidence of disease as shown by MRI for at least 6 months
• Patients known to be HIV positive
• Patients with active autoimmune disease
• Patients involving concurrent anticancer drug therapy
• Patients with unstable medical condition, such as uncontrolled diabetes mellitus or hypertension; active infections requiring systemic antibiotics, antivirals, or antifungals; clinical evidence of cardiac or pulmonary dysfunction including, but not limited to: unstable CHF, uncontrolled arrhythmias, unstable coagulation disorders, or recent myocardial infarction (within 6 months)

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Cellular Therapeutics

UNKNOWN

Sponsor Role: collaborator

The Methodist Hospital Research Institute

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Robert J Amato, DO

Role: PRINCIPAL_INVESTIGATOR

Baylor College of Medicine - Methodist Hospital

Locations

Baylor College of Medicine -Methodist Hospital

Houston, Texas, United States

Countries

United States

Other Identifiers

PCa-X-02

Identifier Type: OTHER

Identifier Source: secondary_id

PAC IRB#03-0192-05

Identifier Type: -

Identifier Source: org_study_id